Form 8-K - Current report:
SEC Accession No. 0000950170-25-077064
Filing Date
2025-05-23
Accepted
2025-05-23 17:00:10
Documents
13
Period of Report
2025-05-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250519.htm   iXBRL 8-K 93594
2 EX-4.1 tcrt-ex4_1.htm EX-4.1 230598
3 EX-10.1 tcrt-ex10_1.htm EX-10.1 396559
4 EX-10.2 tcrt-ex10_2.htm EX-10.2 161662
  Complete submission text file 0000950170-25-077064.txt   1122715

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250519.xsd EX-101.SCH 28389
16 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250519_htm.xml XML 4888
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 25983230
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)